化合物 Dofequidar fumarate,Dofequidar fumarate

化合物 Dofequidar fumarate|T11071|TargetMol

價(jià)格	￥339	￥492	￥813
包裝	1mg	2mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2026-06-29

QQ交談微信洽談

產(chǎn)品詳情

中文名稱(chēng):化合物 Dofequidar fumarate	英文名稱(chēng):Dofequidar fumarate
CAS:153653-30-6	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Keep away from moisture, Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
純度規(guī)格: 99.93%	產(chǎn)品類(lèi)別: 抑制劑
貨號(hào): T001\|T11071

Product Introduction

Bioactivity

名稱(chēng)	Dofequidar fumarate
描述	Dofequidar fumarate (MS-209)(MS-209 fumarate), a quinoline-based compound administered orally, is known for counteracting multidrug resistance (MDR) through the inhibition of ABCB1/P-glycoprotein (P-gp) and ABCC1/MDR-associated protein 1.
體外活性	Dofequidar fumarate effectively overcomes docetaxel resistance in MDR cancer cells, and this concentration reaches> 7 h in plasma without severe toxicity.Dofequidar fumarate restored the chemical sensitivity of SBC-3/ADM cells to VP-16, ADM and VCR in a dose-dependent manner in vitro. Dofequidar inhibits the outflow of chemotherapy drugs and increases the sensitivity of anti-cancer drugs to CSC-like side population (SP) cells isolated from various cancer cell lines. Dofequidar treatment greatly reduces the number of cells in the SP component. In 4-1St cells with strong resistance to ADM and VCR, Dofequidar fumarate at a concentration of 3 microM increased the cytotoxicity of ADM and VCR by 88-fold and 350-fold, respectively.
體內(nèi)活性	Docetaxel alone at the maximum tolerated dose (MTD) has significant antitumor activity against intrinsically resistant HCT-15 tumor xenografts, while Dofequidar fumarate also enhances the antitumor effect of docetaxel active. For MCF-7/ADM tumor xenografts expressing large amounts of P-gp, docetaxel alone did not show antitumor activity at MTD, while the combination of MTD and Dofequidar fumarate for docetaxel greatly reduced MCF -7/ADM tumor growth. Intravenous injection of SBC-3 or SBC-3/ADM cells will produce metastatic colonies in the liver, kidneys, and lymph nodes in severe combined immunodeficiency (SCID) mice depleted by natural killer (NK) cells, although SBC-3/ ADM cells produce faster transfers than SBC-3 cells. The treatment of VP-16 and ADM reduced the formation of metastasis of SBC-3 cells, while the same treatment did not affect the metastasis of SBC-3/ADM cells. Although the use of MS-209 alone has no effect on the transfer of SBC-3 or SBC-3/ADM cells, the combined use of MS-209 and VP-16 or ADM can significantly inhibit the proliferation of SBC-3/ADM cells Metastasis to form an organ.
存儲(chǔ)條件	Keep away from moisture, Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
溶解度	10% DMSO+90% Saline : 10 mg/mL (16.73 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.69 mM), Sonication is recommended. H2O : 1 mg/mL (1.67 mM), Sonication is recommended. DMSO : 125 mg/mL (209.15 mM), Sonication is recommended.
關(guān)鍵字	P-gp \| Pgp \| P-glycoprotein \| Multidrug resistance protein 1 \| MS209 \| MS 209 \| MDR1 \| Inhibitor \| inhibit \| Dofequidar fumarate \| Dofequidar \| Cluster of differentiation 243 \| CD243 \| ABCB1
相關(guān)產(chǎn)品	Bisdemethoxycurcumin \| Trifluoperazine dihydrochloride \| Tariquidar \| Cinchonine \| Glibenclamide \| Bifendate \| Verapamil hydrochloride \| Atazanavir \| Polyoxyethylene stearate \| Atazanavir sulfate \| Encequidar mesylate \| 1-piperoylpiperidine
相關(guān)庫(kù)	抑制劑庫(kù) \| 抗癌活性化合物庫(kù) \| 經(jīng)典已知活性庫(kù) \| 已知活性化合物庫(kù) \| ReFRAME 相關(guān)化合物庫(kù) \| NO PAINS 化合物庫(kù) \| 臨床期小分子藥物庫(kù) \| 膜蛋白靶向化合物庫(kù) \| 口服活性化合物庫(kù) \| 藥物功能重定位化合物庫(kù) \| 抗癌臨床化合物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字： MS-209;TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專(zhuān)業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類(lèi)型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類(lèi)多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專(zhuān)業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （14年）	注冊(cè)資本	566.265100萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 5年

公司成立：14年
注冊(cè)資本：566.265100萬(wàn)人民幣
企業(yè)類(lèi)型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤(pán)

店內(nèi)推薦

化合物 Mycro-3|T4367|TargetMol

￥389

化合物 ABX-464|T8311|TargetMol

詢價(jià)

化合物 PMX-53|T28429|TargetMol

￥7850